Oral lichenoid lesions in HIV-HCV-coinfected subjects during antiviral therapy: 2 cases and review of the literature

American Journal of Dermatopathology

Volumn 30, Issue 5, 2008, Pages 466-471

  Giuliani, Michele ^a   Lajolo, Carlo ^a   Sartorio, Alessandra ^a   Scivetti, Michele ^b   Capodiferro, Saverio ^b   Tumbarello, Mario ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Anti HCV therapy; HAART; HCV; HIV; Oral lichenoid lesions

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; BECLOMETASONE DIPROPIONATE; BETA INTERFERON; CLOBETASOL; CYCLOSPORIN A; DEXAMETHASONE; DIDANOSINE; FLUOCINONIDE; INDINAVIR; INTERFERON; LAMIVUDINE; LYMPHOBLAST INTERFERON; NEVIRAPINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PREDNISONE; RETINOIC ACID; RIBAVIRIN; STAVUDINE; STEROID; TACROLIMUS; TENOFOVIR; TRIAMCINOLONE ACETONIDE; VIRUS RNA; ZIDOVUDINE; ANTIVIRUS AGENT;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL PROTOCOL; DISEASE COURSE; DRUG DOSE REDUCTION; EVENING DOSAGE; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LICHENOID; LIVER BIOPSY; MALE; MIXED INFECTION; MORNING DOSAGE; MOUTH EXAMINATION; MOUTH LESION; MOUTH LICHENOID LESION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; VIRUS LOAD; CASE REPORT; CHEMICALLY INDUCED DISORDER; DIFFERENTIAL DIAGNOSIS; LICHEN PLANUS; LICHENOID ERUPTION; MIDDLE AGED; MOUTH DISEASE; MOUTH MUCOSA; PATHOLOGY; REVIEW;

ANTIVIRAL AGENTS; DIAGNOSIS, DIFFERENTIAL; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; LICHEN PLANUS, ORAL; LICHENOID ERUPTIONS; MALE; MIDDLE AGED; MOUTH DISEASES; MOUTH MUCOSA; RIBAVIRIN;

EID: 58149279370     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/DAD.0b013e31817e23af     Document Type: Article

References (43)

1. Scully C, Beyli M, Ferreiro MC, et al. Update on oral lichen planus: etiopathogenesis and management. Crit Rev Oral Biol Med. 1998;9:86-122.
2. Al-Hashimi I, Schifter M, Lockhart PB, et al. Oral lichen planus and oral lichenoid lesions: diagnostic and therapeutic considerations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103(suppl S25):e1-e12. Epub January 29, 2007.
3. Van der Meij EH, Van der Waal I. Lack of clinicopathologic correlation in the diagnosis of oral lichen planus based on the presently available diagnostic criteria and suggestions for modifications. J Oral Pathol Med. 2003;32:507-512.
4. McCartan BE, McCreary CE. Oral lichenoid drug eruptions. Oral Dis. 1997;3:58-63.
5. Larsson A, Warfvinge G. The histopathology of oral mucosal lesions associated with amalgam or porcelain-fused-to-metal restorations. Oral Dis. 1995;1:152-158.
6. Pereira CM, de Almeida OP, Correa ME, et al. Oral involvement in chronic graft versus host disease: a prospective study of 19 Brazilian patients. Gen Dent. 2007;55:48-51.
7. Protzer U, Ochsendorf FR, Leopolder-Ochsendorf A, et al. Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C. Gastroenterology. 1993;104:903-905.
8. Papini M, Bruni PL, Bettacchi A, et al. Sudden onset of oral ulcerative lichen in a patient with chronic hepatitis C on treatment with alfa-interferon. Int J Dermatol. 1994;33:221-222.
9. Núnez M, Miralles ES, de las Heras ME, et al. Appearance of oral erosive lichen planus during interferon alfa-2a therapy for chronic active hepatitis C. J Dermatol. 1995;22:461-462.
10. Areias J, Velho GC, Cerqueira R, et al. Lichen planus and chronic hepatitis C: exacerbation of the lichen under interferon-alpha-2a therapy. Eur J Gastroenterol Hepatol. 1996;8:825-828.
11. Nagao Y, Sata M, Ide T, et al. Development and exacerbation of oral lichen planus during and after interferon therapy for hepatitis C. Eur J Clin Invest. 1996;26:1171-1174.
12. Schlesinger TE, Camisa C, Gay JD, et al. Oral erosive lichen planus with epidermolytic hyperkeratosis during alfa-2b therapy for chronic hepatitis C virus infection. J Am Acad Dermatol. 1997;36:1023-1025.
13. Nagao Y, Sata M, Suzuki H, et al. Histological improvement of oral lichen planus in patients with chronic hepatitis C treated with interferon. Gastroenterology. 1999;117:283-284.
14. Varela P, Areias J, Mota F, et al. Oral lichen planus induced by interferon-α-N1 in a patient with hepatitis C. Int J Dermatol.2000;39:239-240.
15. Sugiyama T, Shimizu M, Ohnishi H, et al. Clinical evaluation in oral lichen planus with chronic hepatitis C: the role of interferon treatment. Nippon Shokakibyo Gakkai Zasshi. 2000;97:568-574.
16. Guijarro Guijarro B, López Sánchez AF, Hernández Vallejo G. Presence of lichen planus during a course of interferon alpha-2a therapy for a viral chronic C hepatitis. Med Oral. 2001;6:358-363.
17. Nagao Y, Kawaguchi T, Ide T, et al. Exacerbation of oral erosive lichen planus by combination of interferon and ribavirin therapy for chronic hepatitis C. Int J Mol Med. 2005;15:237-241.
18. Armour K, Lowe P. Complicated lichenoid drug eruption. Australas J Dermatol. 2005;46:21-24.
19. National Center for Infectious Diseases Division of HIV/AIDS, Castro KG, Ward JW, et al. Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults. 1993. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm. Accessed March 23, 2008.
20. Benahmed S, Picot MC, Hillaire-Buys D, et al. Comparison of pharmacovigilance algorithms in drug hypersensitivity reactions. Eur J Clin Pharmacol. 2005;61:537-541.
21. Sulkowski M, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med. 2003;138:197-207.
22. Carrozzo M, Gandolfo S. Oral diseases possibly associated with hepatitis C virus. Crit Rev Oral Biol Med. 2003;14:115-127.
23. Sato M, Tokuda N, Fukumoto T, et al. Immunohistopathological study of the oral lichenoid lesions of chronic GVHD. J Oral Pathol Med. 2006;35: 33-36.
24. Sugerman PB, Savage NW, Walsh LJ, et al. The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med. 2002;13:350-365.
25. Shiohara T, Mizukawa Y. The immunological basis of lichenoid tissue reaction. Autoimmun Rev. 2005;4:236-241.
26. De Luca A, Burgarini R, Lepri AC. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naïve HIV-infected subjects. Arch Intern Med. 2002;162:2125-2132.
27. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000;356:1800-1805.
28. Rodriguez B, Lederman MM, Jiang W, et al. Interferon-α differentially rescues CD4 and CD8 T cells from apoptosis in HIV infection. AIDS. 2006;20:1379-1389.
29. Jiang W, Lederman MM, Salkowitz JR, et al. Impaired monocyte maturation in response to CpG oligodeoxynucleotide is related to viral RNA levels in human immunodeficiency virus disease and is at least partially mediated by deficiencies in alpha/beta interferon responsiveness and production. J Virol. 2005;79:4109-4119.
30. Soria A, Lazzarin A. Antiretroviral treatment strategies and immune reconstitution in treatment-naive HIV-infected patients with advanced disease. J Acquir Immune Defic Syndr. 2007;46 (suppl 1):S19-S30.
31. Lehloenya R, Meintjes G. Dermatologic manifestations of the immune reconstitution inflammatory syndrome. Dermatol Clin. 2006;24:549-570, vii.
32. Scully C, Diz Dios P. Orofacial effects of antiretroviral therapies. Oral Dis. 2001;7:205-210.
33. Torriani FJ, Rodriguez-Torres M, Rockstroh JK. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450.
34. Quadri R, Giostra E, Roskams T, et al. Immunological and virological effects of ribavirin in hepatitis C after liver transplantation. Transplantation. 2002;73:373-378.
35. Barnes E, Salio M, Cerundolo V, et al. Impact of alpha interferon and ribavirin on the function of maturing dendritic cells. Antimicrob Agents Chemother. 2004;48:3382-3389.
36. Marinho RT, Pinto R, Santos ML, et al. Effects of interferon and ribavirin combination therapy on CD4+ proliferation, lymphocyte activation, and Th1 and Th2 cytokine profiles in chronic hepatitis C. J Viral Hepat. 2004; 11:206-216.
37. Mignogna MD, Fedele S, Lo Russo L, et al. Unexpected low incidence of oral lichen planus in an HCV hyperendemic area of southern Italy. Gastroenterology. 2001;121:1528-1529.
38. Nagao Y, Tanaka J, Nakanishi T, et al. High incidence of extrahepatic manifestations in an HCV hyperendemic area. Hepatol Res. 2002;22: 27-36.
39. Juneja M, Mahajan S, Rao NN, et al. Histochemical analysis of pathological alterations in oral lichen planus and lichenoid lesions. J Oral Sci. 2006;48:185-193.
40. Raghu AR, Nirmala NR, Sreekumaran N. Direct immunofluorescence in oral lichen planus and oral lichenoid reactions. Quintessence Int. 2002;33: 234-239.
41. Jose M, Raghu AR, Rao NN. Evaluation of mast cells in oral lichen planus and oral lichenoid reaction. Indian J Dent Res. 2001;12:175-179.
42. Khoo SP, Primasari A, Saub R. Nuclear and cellular volumetric alterations immunofluorescence in oral lichen planus and lichenoid lesions: a histomorphometric study. J Oral Sci. 2001;43:151-157.
43. Dubey AK, Prabhu S, Shankar PR, et al. Cutaneous adverse drug reactions to modern medicines and initial experiences from a spontaneous adverse drug reaction reporting program in a tertiary care teaching hospital of Western Nepal. J Pak Assoc Dermatol. 2005;15:222-226